Rotterdam, Netherlands

Anthonie Willem Langerak

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2020-2023

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Anthonie Willem Langerak: Innovator in Minimal Residual Disease Diagnostics

Introduction

Anthonie Willem Langerak is a prominent inventor based in Rotterdam, Netherlands. He has made significant contributions to the field of minimal residual disease (MRD) diagnostics, particularly in relation to hematological malignancies. With a total of 2 patents, Langerak's work is pivotal in improving treatment evaluation for patients suffering from conditions such as B-cell precursor acute lymphoblastic leukemia and multiple myeloma.

Latest Patents

Langerak's latest patents focus on methods, reagents, and kits for detecting minimal residual disease. These inventions are crucial for assessing treatment effectiveness in patients with hematological malignancies. The patents provide unique reagent compositions that include carefully selected combinations of antibodies for ≥8-color flow cytometric stainings, as well as for 10-color and 12-color flow cytometric stainings. These innovations can achieve sensitivities of at least 10, even down to 10, thereby enhancing diagnostic accuracy. Additionally, the patents include diagnostic kits and methods specifically designed for detecting MRD.

Career Highlights

Anthonie Willem Langerak is affiliated with the Erasmus University Medical Center Rotterdam, where he continues to advance research in the field of diagnostics. His work has been instrumental in developing innovative solutions that address critical challenges in the medical field.

Collaborations

Langerak has collaborated with notable colleagues, including Jacobus Johannes Maria Van Dongen and José Alberto Orfao De Matos Correia E Vale. These partnerships have further enriched his research and contributed to the success of his inventions.

Conclusion

Anthonie Willem Langerak stands out as a key figure in the realm of minimal residual disease diagnostics. His innovative patents and collaborations have significantly impacted the evaluation of treatment effectiveness in hematological malignancies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…